Rockwell Medical Inc. (RMTI)
| Bid | 1 |
| Market Cap | 35.42M |
| Revenue (ttm) | 101.49M |
| Net Income (ttm) | -480K |
| EPS (ttm) | -0.03 |
| PE Ratio (ttm) | -34.67 |
| Forward PE | 30 |
| Analyst | Buy |
| Ask | 1.1 |
| Volume | 180,476 |
| Avg. Volume (20D) | 268,972 |
| Open | 1.09 |
| Previous Close | 1.06 |
| Day's Range | 1.03 - 1.10 |
| 52-Week Range | 0.86 - 5.15 |
| Beta | 1.62 |
About RMTI
Rockwell Medical, Inc., together with its subsidiaries, operates as a biopharmaceutical company that targets end-stage renal disease and chronic kidney disease with therapies and products for the treatment of iron deficiency and hemodialysis in the United States and internationally. The company offers Triferic Dialysate and Triferic AVNU, an iron therapy that replaces iron and maintains hemoglobin in dialysis patients without increasing iron stor...
Analyst Forecast
According to 2 analyst ratings, the average rating for RMTI stock is "Buy." The 12-month stock price forecast is $4, which is an increase of 284.62% from the latest price.
Stock Forecasts
1 month ago · businesswire.com
Rockwell Medical to Exhibit at DialysisTechConneXion42 in Booth# 112WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Rockwell Medical will showcase its hemodialysis concentrates portfolio at DialysisTechConneXion42 on April 1-4, 2025 in Las Vegas, NV in...
